The Relationship Between The Differential Expression Of FosB Protein In Laryngeal Cancer Tissues And Clinical Prognosis

First,the investigators will collect 100 to 200 cases of laryngeal cancer patients who have been finally diagnosed and treated in our institution in the past five years. Laryngeal cancer pathological tissues and adjacent tissues will be selected to make pathological sections. Use immunohistochemistry to confirm the differences in FosB protein between laryngeal cancer tissues and adjacent tissues, and clarify whether there are differences.

secondly,if there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. Review the clinical data of corresponding patients, including age, gender, smoking and alcohol history, clinical stages, pathological types and clinical prognosis, etc., and compare whether there are statistical differences.

Finally, clinical prognostic data of relevant patients were collected through outpatient follow-up, online and telephone follow-up, to determine whether there is a correlation between Fosb expression in laryngeal cancer tissue and clinical prognosis.

Inclusion criteria

• laryngeal squamous cell carcinoma was diagnosed ,and biopsy was confirmed by two pathologists;
• Primary tumor of Laryngeal ,and there was no distant metastasis;
• Standard treatment such as surgery and Preliminarily-diagnosed parients;
• full clinical and pathological data information and good follow-up;
• there was no previous fatal diseases such as complicated tumors.

Exclusion criteria

• Secondary cancer or cancer with distant metastasis;
• Patients who have not seen a doctor for the first time or have received surgery or radiotherapy or chemotherapy in other hospitals;
• Clinical and pathological data were missing and loss to follow-up;
• Patients who abandoned treatment or standard treatment procedures has not been completed;
• The past medical history of other lethal diseases such as complicated tumors.